Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts
HLH - Hypoplastic Left Heart Syndrome · DORV · DILV - Double Inlet Left Ventricle · Mitral Atresia · Tricuspid Atresia · Unbalanced AV Canal · Single-ventricle · Heart Defects, Congenital · Cardiovascular Abnormalities · Cardiovascular Diseases · Heart Diseases
De qué trata este estudio
El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.
- Tipo de estudio
- De intervención
- Fase
- Fase 2
- Rango de edad
- No especificado - No especificado
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- No aceptados
- Participantes
- 24 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
A single arm clinical trial evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.
Leer la descripción completa
This investigation is a prospective, open-labeled clinical trial determining the safety of the use of tissue engineered vascular grafts as conduits for EC TCPC. Patients will be monitored for adverse events (AE) and serious adverse events (SAE). Special attention will be paid to the incidence of stenosis. We will determine graft-related morbidity and mortality for the second generation TEVGs which will include any post-operative complication such as any aneurismal dilation, stenosis, thromboembolic or infectious event that requires treatment and is thought to be caused by the graft as determined by the investigators and confirmed by the data safety monitoring board. The graft related complication rates will be compared between the first and second generation TEVGs. An interim analysis will be performed to assess the incidence of early (\<6 month) graft-related complications in the first 6 enrolled patients. Safety and tolerability will be assessed through serial imaging, to determine the effect of growth and remodeling on graft performance through echocardiography and 4-dimensional MRI. All appropriate patients requiring EC TCPC who meet study inclusion/exclusion criteria will be evaluated for enrollment in the clinical trial. All enrolled subjects will be required to have follow-up visits at Nationwide Children's Hospital for a minimum of 2 years following implant. After obtaining informed consent for the patient's parents, patients with single ventricle cardiac anomalies will undergo EC TCPC using a tissue engineered conduit. Post-operative care and monitoring will follow an established, standardized, clinical algorithm in which the patient's clinical status including complications and measurements of graft function will be serially evaluated and recorded over a two year period using physical examination, echocardiography, and MRI.
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria:
- Patients will be eligible for inclusion in the study if they meet all of the following criteria.
1. Patient must be a candidate to undergo an extracardiac total cavopulmonary connection.
2. Patient and/or legal guardian must voluntarily provide informed consent/assent for participation in the study.
Exclusion Criteria:
- Patients will be excluded from participation in the study if they meet any of the following criteria.
1. Patient has an urgent/emergent operative status.
2. Patient has acute renal failure or renal insufficiency in the opinion of the investigator
3. Patient requires a graft less than 12 mm or greater than 24 mm in diameter.
4. Patient has a pacemaker.
5. Patient has pulmonary vascular resistance greater than 4 um2 (u=Wood's units)
6. Patient has abnormal venous drainage (interrupted inferior vena cava \[IVC\]).
7. Patient presents with significant atrio-ventricular valve regurgitation that in the opinion of the investigator, makes them ineligible.
8. Patient has a history of another condition or significant medical problem that, in the opinion of the investigator, precludes compliance with protocol-specified procedures.
9. Patients taking any medications that in the opinion of the Investigator could interfere with the TEVG, including bisphosphonates (i.e. Clodronate or Zoledronate).
10. Patient or parent/legal guardian is, in the opinion of the investigator, unable to comply with protocol evaluations.
11. Preoperative hemoglobin \<11.0 mg/dL at time of patient's pre-admission testing.
Tratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- No aplica
- Enmascaramiento
- Sin enmascaramiento
Tissue Engineered Vascular Grafts
No informado en este registro.
Combination Product: Tissue Engineered Vascular Grafts
Tissue Engineered Vascular Grafts COMBINATION_PRODUCT
Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance imaging (MRI)
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Safety and Tolerability of TEVG
Plazo: 2 years
Assessed through graft related complications as determined by serial echocardiogram
Safety and Tolerability of TEVG
Plazo: 2 years
Assessed through graft related complications as determined by serial MRI
Safety and Tolerability of TEVG
Plazo: 2 years
Assessed through adverse events
Medidas secundarias
Efficacy of TEVG
Plazo: 2 years
Evaluate graft performance based on MRI
Efficacy of TEVG
Plazo: 2 years
Measured graft volume(mL) as determined by MRI
Efficacy of TEVG
Plazo: 2 years
Measured graft length (mm) as determined by MRI
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (1)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
1 centros
Nationwide Children's HospitalColumbus, Ohio, United StatesReclutando
Equipo y fechas
- Patrocinador principal
- Nationwide Children's Hospital
- Inicio del estudio
- 15 jul 2020 Real
- Finalización primaria
- 2029-12 Estimado
- Finalización del estudio
- 2031-12 Estimado
- Primera publicación
- 13 jul 2020 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection.
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026